Repare Therapeutics

Repare Therapeutics

Repare Therapeutics

Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Raised
$68M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$68,000,000
Venture capital (Series A) - 2017
Fonds de solidarité FTQ Celgene MPM Capital +2
Team Size
1–10
Employees
Location
Headquarters
Pulse 2.0

Repare Therapeutics (RPTX) Stock: $30 Target And Overweight Rating

Pulse 2.0

Repare Therapeutics (RPTX) Stock Price: Why It Increased Over 20% Today

Pulse 2.0

Repare Therapeutics (RPTX) Stock: $48 Price Target From Stifel

Xconomy

After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO

FinSMEs

Repare Therapeutics Raises US$82.5M in Series B Financing

$68,000,000 Venture capital (Series A)
Funding Report , 4-traders

Quebec's Repare Therapeutics raises $68M in Series A funding